Clinical trials: Severe Pneumonia
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
SARS-CoV Infection
Remdesivir in COVID-19 Lahore General Hospital
Remdesivir is a monophosphoramidate prodrug of an adenosine analogue and it has a broad-spectrum antiviral activity against paramyxoviruses, falviviruses and coronaviruses.
- Trial name
- RC19LGH (NCT04560231)
- Testing
- Remdesivir
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Lahore General Hospital
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
SARS-CoV-2 Infection
REMdesivir-HU Clinical Study and Severe Covid-19 Patients
This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.
- Trial name
- NCT04610541
- Testing
- Remdesivir-HU
- Where
- 7 sites in Hungary
- Volunteers
- 2,000 people
- Sponsor
- University of Pecs
Virus Diseases
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases.
- Trial name
- COVIMAR (NCT04710199)
- Testing
- Maraviroc experimental group, Standard treatment
- Where
- 2 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Coronavirus Disease 2019 (COVID-19)
Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency
In this prospective observational study we aim to study the association of vitamin D deficiency with adverse clinical outcomes in patients infected with Coronavirus disease 2019
- Trial name
- COVIT-D (NCT04403932)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital San Carlos, Madrid
COVID 19
Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19
Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with severe COVID-19.
- Trial name
- NCT06585319
- Testing
- Collagen-polyvinylpyrrolidone, Pirfenidone 1200 mg
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Materno-Perinatal Hospital of the State of Mexico
Covid-19
Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)
A comparison of a direct antigen test for SARS-CoV-2 obtained by mid-turbinate swab with the reference standard rt-PCR test obtained by nasopharyngeal swab in outpatients with symptoms compatible with COVID-19.
- Trial name
- NCT04610489
- Testing
- Quidel Sofia SARS Antigen FIA
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Carilion Clinic
Healthcare-Associated Pneumonia, Ventilator Associated Pneumonia
HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study
The use of corticosteroids in patients with severe community pneumonia, bacterial infection which kills lots of patients around the world, reduces the mortality of this infection.
- Trial name
- HYDRO-SHIP (NCT05354778)
- Testing
- Hydrocortisone
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo
COVID-19
Postural Changes and Severe COVID-19
COVID-19 remains a widespread global epidemic, increasing morbidity, mortality, healthcare resource consumption, and socio-economic burden on patients worldwide.
- Trial name
- NCT05679440
- Testing
- Postural interventions based on pulmonary imaging
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Severe Community-acquired Pneumonia (sCAP)
Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea
This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and…
- Trial name
- ACTSCAP (NCT06977347)
- Testing
- Piperacillin/Tazobactam, Piperacillin/tazobactam + Levofloxacin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHOSEOK YOON
Covid19, SARS-CoV Infection
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
Adults (aged 18-65 years) recently diagnosed with SARS-CoV-2 infection who use a 4-day combined intervention of nasal washes with 1% baby shampoo solution and oral gargles with Listerine Antiseptic® will have a reduced SARS-CoV-2…
- Trial name
- SNOW (NCT04802408)
- Testing
- Saline and Listerine, Saline and Saline
- Where
- 2 sites in United States
- Volunteers
- 171 people
- Sponsor
- Milton S. Hershey Medical Center
Community-Acquired Pneumonia (CAP), Pneumonia
Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial
Community-acquired pneumonia (CAP) is among the most common reasons for emergency department (ED) visits. A clear understanding of the likely pathogens is essential for the rapid institution of adequate antimicrobial therapy.
- Trial name
- CIRT-RMT-SARI (NCT06605352)
- Testing
- The BIOFIRE®FILMARRAY® Pneumonia Panel
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- National Taiwan University Clinical Trial Center
Covid19, Corona Virus Infection
Adolescents With COVID-19/MIS-C at HCFMUSP
This is a protocol aimed at children and adolescents contaminated with COVID, treated at the Hospital das Clínicas, University of Sao Paulo, Brazil (HCFMUSP), in the recovery phase.
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection
- Trial name
- NCT04659486
- Testing
- Home-based exercise training
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19 Related Health and Infection Control Practices Among Dentists
As dentists begin reopening their practices during a global pandemic, the risk of COVID-19 infection that dentists face in providing dental care remains unknown.
- Trial name
- NCT04423770
- Testing
- No intervention
- Where
- United States
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- American Dental Association
COVID-19
Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk…
- Trial name
- NCT04323631
- Testing
- Hydroxychloroquine, The control group will not receive hydroxychloroquine
- Sponsor
- Rambam Health Care Campus
Acute Respiratory Distress Syndrome, Pneumonia
Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia
This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.
- Conditions
- Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection
- Trial name
- iGRASP (NCT02601365)
- Testing
- Sargramostim 0.04 mcg/kg/dose, Sargramostim 0.2mcg/kg/dose, Sargramostim 1 mcg/kg/dose
- Sponsor
- Milton S. Hershey Medical Center
Respiratory Viral Infection, Covid19
Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control.
- Trial name
- COVIDRASP (NCT04496245)
- Testing
- Broncho-Vaxom®
- Where
- 3 sites in Australia
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Covid19
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- TESICO (NCT04843761)
- Testing
- Remdesivir, Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 473 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Using Mixed-methods Approach to Explore the Long-term Effects of COVID-19
Researchers warned that up to 80% of the survivors may experience multiple and severe long-term symptoms, sometimes called Long Coronavirus Disease(Long COVID).
- Trial name
- NCT05303103
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.